Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

02/06/2021 Parc de l’Alba in a WHO publication on the redevelopment of contaminated sites 27/04/2021 Natura Bissé: when architecture reflects the brand identity 08/04/2021 ASTIP, the future hub for advanced research in the Barcelona Synchrotron Park 25/03/2021 4th anniversary of the setting up of Stradivarius headquarter in the Barcelona Synchrotron Park 05/03/2021 T-Systems, a leading IT service provider with a Data Centre in the Barcelona Synchrotron Park 18/02/2021 SENER participates in the Perseverance rover which is landing on Mars today
1 2 3 4 5 6 7